Joint Pain News and Research

RSS

Researchers explore the fate of dietary fructose in the body

In today's fast-paced world, the dependence on the widely available "fast" foods and beverages has risen. These foods are typically low in fiber and essential nutrients, and often consist of high amounts of added sugar. This shift in dietary trends, accompanied by a sedentary lifestyle, has been attributed to the rise in various metabolic disorders like diabetes, fatty liver disease, and heart disease.

31 Aug 2021

New AHA Presidential Advisory addresses opioid use and its effects on heart and brain health

The misuse of opioids in the United States continues to lead to high rates of dependency as well as a staggering number of deaths due to overdose.

19 Aug 2021

FDA approves an intravenous medication to treat patients with Pompe disease

Today, the U.S. Food and Drug Administration approved Nexviazyme (avalglucosidase alfa-ngpt) for intravenous infusion to treat patients 1 year of age and older with late-onset Pompe disease.

6 Aug 2021

Study reports on COVID-19 vaccine-related adverse events in young Japanese population

A new study from Japan, released as a medRxiv* preprint, describes the adverse effects associated with the vaccine. Such data is crucial in delineating the safety and efficacy of this intervention in various age groups.

6 Aug 2021

Flu vaccine may provide vital protection against COVID-19, study shows

In a newly published study, physician-scientists at the University of Miami Miller School of Medicine have shown that the flu vaccine may provide vital protection against COVID-19.

4 Aug 2021

Novel type of cellular therapy safe for knee pain caused by osteoarthritis, study confirms

A study released in STEM CELLS Translational Medicine has confirmed the safety of a novel type of cellular therapy for knee pain caused by osteoarthritis.

3 Aug 2021

Poll: Reduced activity during the pandemic may have increased older adults' fall risk

The COVID-19 pandemic may have increased older adults' risk of falling and injuring themselves, due to changes in physical activity, conditioning and mobility, a new national poll suggests.

3 Aug 2021

New study disproves suspicion that dengue raises risk of zika-related microcephaly

A pregnant woman infected by zika virus does not face a greater risk of giving birth to a baby with microcephaly if she has previously been exposed to dengue virus, according to a Brazilian study that compared data for pregnant women in Rio de Janeiro and Manaus.

20 Jul 2021

$50,000 grant to help explore the use of turmeric for reducing joint pain in breast cancer patients

UC Davis Comprehensive Cancer Center received a $50,000 grant from the Safeway Foundation to explore the use of the South Asian spice Turmeric as a way of reducing joint pain in breast cancer patients being treated with anti-estrogen drugs.

16 Jul 2021

Women at higher risk of post-COVID-19 syndrome

To better understand post-COVID sequelae, researchers at the University Hospital Basel and the University Hospital Zurich conducted a multicentre prospective observational cohort study.

8 Jul 2021

Exploring young people’s perspectives on patient-reported outcome measures in inflammatory arthritis

Inflammatory arthritis is the name for a group of diseases that cause joint pain and swelling. This happens because the body's immune system attacks its own tissues and causes inflammation.

23 Jun 2021

Device makers have funneled billions to orthopedic surgeons who use their products

Dr. Kingsley R. Chin was little more than a decade out of Harvard Medical School when sales of his spine surgical implants took off.

17 Jun 2021

Myocarditis after SARS-CoV-2 vaccine

A group of Italian researchers has published a study in the Canadian Journal of Cardiology (CJC), that explores a rare case of progressive dyspnea and constrictive retrosternal pain after a SARS-CoV-2 vaccine.

17 Jun 2021

Joint ICMRA and WHO statement explains how COVID-19 vaccines are regulated for safety, effectiveness

Healthcare professionals and public health authorities have a central role in discussing vaccination against COVID-19 with their patients.

13 Jun 2021

Are women more likely to develop long COVID?

Researchers found different groups of symptoms persisting after coronavirus disease 2019 (COVID-19), with fatigue and higher IL-6 levels common in women. About 75% of the patients they treated were women, indicating a link between sex hormones and immune response.

8 Jun 2021

FDA approves new treatment for patients with hypoplasminogenemia

Today, the U.S. Food and Drug Administration approved Ryplazim (plasminogen, human-tmvh) for the treatment of patients with plasminogen deficiency type 1, also referred to as hypoplasminogenemia, a disorder that can impair normal tissue and organ function and may lead to blindness.

5 Jun 2021

NIH launches first-in-human, Phase 1 trial assessing investigational nanoparticle influenza vaccine

A first-in-human, Phase 1 trial assessing the safety and immunogenicity of an investigational nanoparticle influenza vaccine designed to provide long-lasting protection against multiple flu virus strains has begun at the National Institutes of Health Clinical Center in Bethesda, Maryland.

1 Jun 2021

SWOG researchers to present practice-changing research at virtual ASCO 2021

"SWOG always brings an impressive portfolio of work to the ASCO annual meeting," said SWOG Chair Charles D. Blanke, MD, "and this year I'm particularly excited about the research our investigators are presenting because it includes results that are likely to be practice-changing."

1 Jun 2021

Effect of COVID-19 pandemic on patients with rheumatoid arthritis, systemic lupus erythematosus

In the Philippines, in the early months of the COVID-19 pandemic, there occurred a supply shortage of hydroxychloroquine and methotrexate. Limited access to medication and the life changes caused from the COVID-19 pandemic may prompt patients with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) to experience disease flares.

29 May 2021

FDA approves Rybrevant for treating subset of non-small cell lung cancer

Today, the U.S. Food and Drug Administration approved Rybrevant (amivantamab-vmjw) as the first treatment for adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations.

21 May 2021